Physician profile
John E Lacy
NPI 1992964159
$827.16
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $51.80 · 2021: $105 · 2022: $326 · 2023: $111 · 2024: $18.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $128.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $137.90 | 2019-2023 | Tresiba, Rybelsus, Ozempic |
| Dexcom, INC. | $113.69 | 2022-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $89.82 | 2019-2022 | |
| Pfizer INC. | $72.32 | 2021-2022 | |
| Inari Medical, INC. | $69.25 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $53.26 | 2019 | |
| Abbott Laboratories | $49.01 | 2020-2022 | |
| Glaxosmithkline, LLC. | $43.81 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $30.86 | 2019 | |
| Abbvie INC. | $28.49 | 2021-2022 | |
| Mannkind Corporation | $22.74 | 2021 | |
| Philips North America LLC | $21.85 | 2019 | |
| Biosense Webster, INC. | $19.05 | 2019 | |
| Sumitomo Pharma America, INC. | $18.00 | 2024 | Gemtesa |
| Allergan, INC. | $16.77 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $15.36 | 2019 | |
| Merck Sharp & Dohme LLC | $14.09 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lacy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.